Last reviewed · How we verify
FST-100
At a glance
| Generic name | FST-100 |
|---|---|
| Sponsor | Shire |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis (PHASE2)
- FST-100 in the Treatment of Acute Adenoviral Conjunctivitis (PHASE2)
- FST-100 in the Treatment of Acute Viral Conjunctivitis (PHASE2)
- Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FST-100 CI brief — competitive landscape report
- FST-100 updates RSS · CI watch RSS
- Shire portfolio CI